ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.

ALXO has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group lowered shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their price target for the stock from $12.00 to $2.00 in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Wednesday, December 18th.

Insider Buying and Selling

In other news, Director Rekha Hemrajani purchased 30,000 shares of ALX Oncology stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. The trade was a 1,000.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 33.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On ALX Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALXO. Marshall Wace LLP increased its stake in shares of ALX Oncology by 423.0% in the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after purchasing an additional 514,133 shares during the last quarter. Privium Fund Management B.V. boosted its stake in ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after buying an additional 112,093 shares in the last quarter. Renaissance Technologies LLC grew its position in ALX Oncology by 87.2% in the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after acquiring an additional 204,100 shares during the last quarter. XTX Topco Ltd acquired a new position in ALX Oncology during the third quarter worth about $578,000. Finally, Point72 Asset Management L.P. bought a new position in shares of ALX Oncology in the second quarter worth about $1,834,000. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Stock Up 9.5 %

Shares of ALXO opened at $1.62 on Monday. The firm’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $3.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm has a market cap of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.